Short Interest in Protara Therapeutics, Inc. (NASDAQ:TARA) Grows By 510.9%

Protara Therapeutics, Inc. (NASDAQ:TARA) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totalling 398,300 shares, a growth of 510.9% from the March 31st total of 65,200 shares. Approximately 4.4% of the shares of the stock are sold short. Based on an average daily volume of 250,200 shares, the days-to-cover ratio is currently 1.6 days.

Analysts Set New Price Targets

TARA has been the subject of several research reports. Oppenheimer increased their price objective on shares of Protara Therapeutics from $26.00 to $30.00 and gave the company an “outperform” rating in a research report on Monday, April 22nd. HC Wainwright reissued a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a research note on Monday, April 8th.

Protara Therapeutics Stock Performance

Protara Therapeutics stock traded down $0.12 during midday trading on Friday, hitting $2.93. 255,029 shares of the company’s stock were exchanged, compared to its average volume of 623,671. Protara Therapeutics has a 12 month low of $1.04 and a 12 month high of $5.24. The firm has a 50-day moving average of $3.72 and a two-hundred day moving average of $2.50. The company has a market cap of $33.43 million, a PE ratio of -0.82 and a beta of 1.71.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.03) by $0.13. As a group, equities analysts expect that Protara Therapeutics will post -3.55 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.